Statins and Solid Organ Transplantation

Author(s): I. F. Gazi, E. N. Liberopoulos, V. G. Athyros, M. Elisaf, D. P. Mikhailidis

Journal Name: Current Pharmaceutical Design

Volume 12 , Issue 36 , 2006

Become EABM
Become Reviewer
Call for Editor


Dyslipidaemia is common in solid organ transplant recipients and its presence is associated with chronic rejection and accelerated atherosclerosis, leading to an increased prevalence of cardiovascular disease (CVD). CVD is a major cause of morbidity and mortality in transplant recipients. It is therefore of interest and clinical value to introduce agents that effectively and safely reduce the incidence of this outcome. In the present review we consider the potential benefits of statin administration in adults who have undergone solid organ (mainly renal, heart and liver) transplantation, as well as in paediatric transplant patients. We also briefly review the effects of combination therapy with ezetimibe and statins in this population. Overall, statins are efficient and safe drugs for the management of dyslipidaemias in transplant populations, and in most trials they had a beneficial effect on long-term survival rates, CVD events and rejection rates. The transplanted population is different from other patient groups, mostly due to concomitant immunosuppressive therapy. Statins, at an appropriate dosage, should be prescribed to dyslipidaemic transplanted patients but they should be closely monitored for adverse effects.

Keywords: Statins, dyslipidaemia, transplantation, cardiovascular disease, atherosclerosis, rejection

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2006
Page: [4771 - 4783]
Pages: 13
DOI: 10.2174/138161206779026308
Price: $65

Article Metrics

PDF: 10